Goal 3

What Goal 3 does

GOAL 3 B.V. is a Netherlands-based social enterprise founded in September 2019 that develops the IMPALA patient monitoring system, an end-to-end clinical support solution purpose-built for hospitals in low-resource settings in sub-Saharan Africa. IMPALA comprises three integrated components: a continuous multi-parameter vital-sign patient monitor (tracking ECG heart rate, ECG respiratory rate, SpO2, and temperature), a server-connected IMPALA Platform providing central patient overview, clinical decision support, and data dashboards, and IMPALA Care, a service package covering training, remote troubleshooting, quarterly check-ins, and spare parts supply. The system is engineered for durability, long battery life, and intuitive operation with minimal training, and incorporates proprietary age-specific alarm algorithms and ML-based predictive deterioration models trained on data from approximately 772 patients in Malawi.

GOAL 3 generates revenue through a hybrid commercial-and-philanthropic model: direct IMPALA hardware sales at €2,500 per monitor, multi-year service and maintenance subscription contracts, and a foundation/donation channel operated via the GOAL 3 Foundation that enables under-resourced hospitals to receive systems through monthly donations of €50 over five years. The company also derives significant non-dilutive funding from research and humanitarian grants, including pre-seed crowdfunding of €657,100 (February 2021), the Achmea Foundation Grant (July 2021), an EDCTP clinical trial grant, the €150,000 EU Prize for Humanitarian Innovation (March 2024), a $260,000 Founders Pledge grant (September 2024), and a €1M Eurostars grant with Picterus AS (January 2026).

GOAL 3 serves hospitals and government health ministries in Malawi, Rwanda, and Tanzania, with field operations coordinated through country managers in each market and a regional East Africa hub via GOAL 3 Rwanda Ltd. (founded October 2022). Customers include St. Luke's Hospital, Queen Elizabeth Central Hospital, Zomba Central Hospital, Sengerema Hospital, University Teaching Hospital CHUK, and Nyamata Hospital. Documented clinical outcomes include up to 51% reduction in pediatric mortality, 47% reduction in critical events, 45% reduction in monitoring time per shift, and an estimated cost per life saved of $100-250. The company employs approximately 26 people across engineering, clinical, country operations, and business development roles.

Name

Goal 3

Legal name

Goal 3 B.V.

Website

https://goal3.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

GOAL 3 develops the IMPALA patient monitoring and clinical decision support system for hospitals in low-resource African settings. It sells hardware, multi-year service subscriptions, and accepts donations through its foundation to deploy across Malawi, Rwanda, and Tanzania.

Ownership category

akta.pro rank

Product category

Medical Patient Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

In-Home Landline PERS & Base-Unit Medical Alert Services (HSAHAHAB)

Keywords

• Patient monitoring systems
• Clinical decision support
• Medical devices
• Vital sign monitoring
• Healthcare technology

Headquarters

HQ city

's-hertogenbosch

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. IMPALA Hardware Sales: Sale of IMPALA patient monitoring systems to hospitals and healthcare facilities. Monitor costs €2,500 upfront per unit or €50/month for 5 years through the foundation donation model.
2. Service Subscriptions: Ongoing subscription contracts covering service, maintenance, and software upgrades ensure sustainability of IMPALA implementations at partner hospitals.
3. Foundation/Donation Model: The GOAL 3 Foundation accepts donations to subsidize IMPALA monitor costs for hospitals that cannot afford commercial pricing, enabling broader reach in rural and under-resourced facilities.
4. Research and Grant Funding: GOAL 3 receives grants from organizations like Founders Pledge ($260,000), EDCTP, and Eurostars (€1M with Picterus) for research, validation studies, and product development.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Goal 3 develops and sells the IMPALA system, an end-to-end ward-level clinical support solution for hospitals in low-resource settings. IMPALA combines a continuous multi-parameter vital sign patient monitor with a clinical support platform (central patient overview, dashboards, real-time alerts) and a comprehensive service package (IMPALA Care) covering training, maintenance, spare parts, and remote support. The system is purpose-built for pediatric and neonatal wards in sub-Saharan African hospitals.

Product overview

GOAL 3's product portfolio centers on the IMPALA Solution, an end-to-end clinical support system for health facilities in low-resource settings. The system comprises three integrated components: the IMPALA Patient Monitor (a continuous multi-parameter vital sign monitor with hardware and sensors), the IMPALA Platform (a server-connected clinical support application providing patient overview dashboards, decision support, and data analytics), and IMPALA Care (a full-service support package covering training, maintenance, and spare parts). The three components work together as a unified system: the monitor captures vital signs at the bedside, the platform aggregates and analyzes that data to generate early warnings and prioritization insights, and IMPALA Care ensures sustainable deployment through training, remote troubleshooting, and local service teams. The system is designed specifically for low-resource hospitals in Africa and aims to shift healthcare from reactive to proactive care.

Differentiator

Problem solved

Functional benefit

Brands

• IMPALA: End-to-end clinical support system for health facilities in low-resource settings, consisting of IMPALA Monitor (continuous vital sign patient monitor), IMPALA Platform (central patient overview and clinical support application), and IMPALA Care (service package for sustainability).
• JaundiceCARE

Products and services

• IMPALA Patient Monitor A fit-for-context continuous multi-parameter vital sign patient monitor designed for low-resource settings. Continuously tracks ECG heart rate, ECG respiratory rate, oxygen saturation (SpO2), and temperature with a user-friendly touchscreen that requires minimal training. Sold to hospitals and healthcare facilities.
• IMPALA Platform A clinical decision support software platform comprising a Central Patient Overview dashboard, Clinical Support Application, and Data Dashboard. Connects to the patient monitor via a server, providing real-time data analysis, patient prioritization, clinical history tracking, and ward-level analytics. Sold as part of the IMPALA system to hospitals.
• IMPALA Care A comprehensive service package bundled with IMPALA implementations covering a Champions program, e-learning modules, an IMPALA WhatsApp community, staff onboarding tools, remote system troubleshooting, quarterly remote system check-ins, spare parts and consumables supply, and local service team support. Sold as multi-year subscriptions to partner hospitals.
• JaundiceCARE An AI-powered newborn jaundice management system being developed in partnership with Picterus AS that combines smartphone-based non-invasive jaundice screening with IMPALA continuous monitoring. Targeted at low-resource hospitals in Tanzania.

Quantifiable outcome

• 51% reduction in pediatric mortality
• +11 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Picterus AScoreStrategic or Co-development Partner · 28 January 2026Norwegian partner with whom GOAL 3 secured a €1 million Eurostars grant to develop JaundiceCARE, an AI-powered newborn jaundice management system combining Picterus Jaundice Pro with GOAL 3 IMPALA monitoring.
• AMREF MalawicoreImplementation/ SI/ Consulting Partner · 1 January 2023AMREF Malawi partnered with GOAL 3 for implementation of IMPALA systems in Malawian hospitals. AMREF provided national trainers for neonatal care training and implementation support.
• AIGHD (Amsterdam Institute for Global Health and Development)coreStrategic or Co-development Partner · 1 June 2021Lead partner in the IMPALA Project consortium. AIGHD leads a consortium including Amsterdam UMC, Leiden University Medical Center, National eHealth Living Lab, University of Malawi College of Medicine, and Imperial College London for research, development and implementation of the IMPALA monitoring system.
• Mango Product DesigncoreStrategic or Co-development PartnerDesign firm collaborated with GOAL 3 to develop the IMPALA 1.0 product design released in March 2022. The resulting design with firm handle, green sleeve, and durable appearance created an iconic design suited for the end-users' environment. Both companies received the iF Design Award together.
• Amsterdam UMCcoreStrategic or Co-development PartnerClinical partner in the IMPALA Project consortium. Dr. Job Calis from Amsterdam Medical Center helped design the clinical pilot study and provided pediatric intensive care expertise.
• University of Malawi, College of MedicinecoreStrategic or Co-development PartnerLocal academic partner in Malawi supporting the IMPALA clinical studies and providing expertise on healthcare in the Malawian context.
• Imperial College LondonminorStrategic or Co-development PartnerAcademic partner in the IMPALA Project consortium providing research and development expertise.
• Leiden University Medical CenterminorStrategic or Co-development PartnerAcademic partner in the IMPALA Project consortium contributing to research and development activities.
• National eHealth Living Lab (NeLL)minorStrategic or Co-development PartnerPartner providing expertise in digital health implementation and eHealth living lab methodologies for the IMPALA project.
• Paediatric Association of TanzaniacoreStrategic or Co-development PartnerPartner for clinical validation of the JaundiceCARE system in Tanzanian hospitals. Dr. Theopista Masenge, President of the association, endorsed the collaboration noting Tanzania's excitement for the breakthrough technology.
• Rwanda Ministry of HealthcoreStrategic or Co-development PartnerGOAL 3 signed an MOU with the implementation branch of the Ministry of Health of Rwanda as a main partner. Ministry provided RFDA approval for IMPALA implementation in three hospitals in Rwanda in August 2024.

Scale indicators19 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Laerdal Global Health: Norwegian nonprofit arm of Laerdal that develops affordable medical training simulators and selected clinical devices for low-resource settings. Closely comparable to GOAL 3 in target customer (LMIC frontline health workers) and mission-driven model.
• Neopenda: US-based healthtech startup developing wearable vital sign monitors specifically for newborns in low-resource African hospitals. Highly comparable to GOAL 3's IMPALA on product (continuous multi-parameter vital sign monitoring), customer (African hospitals), and target user (frontline health workers in LMICs).
• Gradian Health Systems: US/UK nonprofit medical equipment company building anesthesia machines, ventilators, and patient monitors engineered for low-resource hospitals. Directly comparable as a medical-device-for-LMICs peer with similar mission, customer base, and durable-design philosophy.
• Lifebox: Global nonprofit that distributes affordable pulse oximeters and surgical safety tools to hospitals in low- and middle-income countries. Comparable to GOAL 3 as a mission-aligned medical-device distributor for LMIC hospitals with similar global-health funding model.

Broad incumbents

• GE HealthCare: Global medical technology leader with the CARESCAPE and Portrait patient monitoring lines. Comparable as a broad incumbent whose portfolio overlaps GOAL 3's category and whose scale and global-health programs could threaten niche LMIC players.
• Mindray: Major Chinese medical device manufacturer with a global multi-parameter patient monitor line (BeneVision, ePM series). A potential competitor for hospital monitoring in emerging markets and an alternative for any hospital evaluating GOAL 3.
• Masimo: US-based manufacturer of pulse oximetry, patient monitoring, and connectivity solutions. Adjacent incumbent with overlapping vital-sign technology that could be deployed in LMIC settings with appropriate ruggedization.
• Philips Foundation: Royal Philips's philanthropic arm (Philips parent makes patient monitors at scale, and Philips Foundation is already a partner of GOAL 3). Comparable as a global patient-monitoring incumbent that could expand dedicated LMIC offerings and compete with GOAL 3's niche.

Emerging players

• Wellspring Medical: Emerging Chinese-origin manufacturer of low-cost patient monitors and infusion pumps targeted at emerging markets. Comparable as a smaller-scale competitor in the affordable vital-sign monitor category for LMIC hospitals.
• Picterus: Norwegian startup developing smartphone-based non-invasive newborn jaundice screening (Picterus Jaundice Pro). Active GOAL 3 partner in the JaundiceCARE Eurostars project; comparable as an emerging LMIC-focused neonatal medical device player with complementary rather than competing offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@goal3570
• Facebookfacebook.com/GOAL3.WeAllHealth
• LinkedInlinkedin.com/company/goal3

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Goal 3